Patents by Inventor J Cannon Clifton

J Cannon Clifton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230277568
    Abstract: Methods for treatment for patients suffering from disease or condition are contemplated as including an administration of an intravenous infusion of a pharmaceutically effective amount of psilocybin or psilocin. The intravenous infusion of psilocybin or psilocin may include an additional compound such as a benzodiazepine, preferably lorazepam, administered via a continuous intra-venous infusion. Such methods may be seen to better alleviate the symptoms of psychological conditions, neurological injuries, pain, or inflammatory condition, and may result in reduced need for other medications.
    Type: Application
    Filed: July 12, 2021
    Publication date: September 7, 2023
    Inventors: Ryan Steven BRIDGES, J. Cannon CLIFTON, John Bryan CLIFTON, Neiloufar FAMILY, Emeline L. MAILLET, Shlomi RAZ, David E. NICHOLS, Charles D. NICHOLS
  • Patent number: 11154537
    Abstract: Methods for treatment for patients having depression and/or pain are contemplated as including an administration of first preparation comprising an antiemetic agent, preferably ondansetron, followed by a second preparation of a synergistic combination of ketamine and a benzodiazepine, preferably lorazepam, administered via a continuous intravenous infusion. Such methods may be seen to better alleviate depression and pain symptoms, and may result in reduced need for other medications.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: October 26, 2021
    Assignee: Eleusis Therapeutics US, Inc.
    Inventors: John Bryan Clifton, J Cannon Clifton, Mark Alan Moran, Scott Patrick Worrich
  • Publication number: 20210322384
    Abstract: Methods for treatment for patients having depression and/or pain are contemplated as including an administration of first preparation comprising an antiemetic agent, preferably ondansetron, followed by a second preparation of a synergistic combination of ketamine and a benzodiazepine, preferably lorazepam, administered via a continuous intravenous infusion. Such methods may be seen to better alleviate depression and pain symptoms, and may result in reduced need for other medications.
    Type: Application
    Filed: July 1, 2021
    Publication date: October 21, 2021
    Applicant: Eleusis therapeutics us, inc.
    Inventors: John Bryan Clifton, J Cannon Clifton, Mark Alan Moran, Scott Patrick Worrich
  • Publication number: 20200046683
    Abstract: Methods for treatment for patients having depression and/or pain are contemplated as including an administration of first preparation comprising an antiemetic agent, preferably ondansetron, followed by a second preparation of a synergistic combination of ketamine and a benzodiazepine, preferably lorazepam, administered via a continuous intravenous infusion. Such methods may be seen to better alleviate depression and pain symptoms, and may result in reduced need for other medications.
    Type: Application
    Filed: August 10, 2018
    Publication date: February 13, 2020
    Inventors: John Bryan Clifton, J Cannon Clifton, Mark Alan Moran, Scott Patrick Worrich